MAP1LC3A and hypopharynx cancer: LC3 was increased in 53% of esophageal cancer, 58% of GC, and 63% of colorectal cancer (Yoshioka et al. 2008), while LC3 in hypopharyngeal cancer and renal clear cell cancer was decreased (Wang et al. 2013).